RxDoctor Payments DataLook up a doctor →

Clarence Kemp, MD

Family Medicine · Paragould, ARNPI 1700849684

Payments from drug & device makers

$16,045in general payments, 2019–2025

Across 1,051 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$1K
  • Amgen$1K
  • Pfizer$866
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$15,88099%
  • Education$1651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,045 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$80,041
Medicare patients
307
Services billed
2,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$69,280
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$48,980
JanuviaSitagliptin Phosphate44$35,199
EntrestoSacubitril/Valsartan41$34,408
VraylarCariprazine Hcl14$23,484
XareltoRivaroxaban39$21,371
LinzessLinaclotide17$16,444
JardianceEmpagliflozin19$14,974
Combivent RespimatIpratropium/Albuterol Sulfate29$13,959
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen473$10,836
MultaqDronedarone Hcl11$8,635
SavellaMilnacipran Hcl13$6,133
Albuterol Sulfate HfaAlbuterol Sulfate156$4,669
ShingrixVaricella-Zoster Ge/As01b/Pf21$4,555
Alprazolam663$4,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$866$69,28089 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$1,274$57,32790 claims
AbbVieVraylar, Linzess, Savella$2,344$46,06244 claims
MerckJanuvia$274$35,19944 claims
NovartisEntresto$178$34,40841 claims
Boehringer IngelheimJardiance, Combivent Respimat$304$28,93348 claims
Johnson & JohnsonXarelto$12$21,37139 claims
Sanofi-aventis U.S. LLCMultaq$86$8,63511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Paragould

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →